Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials

Australian and New Zealand Journal of Psychiatry

Volumn 48, Issue 7, 2014, Pages 663-671

  Huang, Kai Lin ^a   Lu, Wan Chen ^a   Wang, Ying Yue ^a   Hu, Gwo Chi ^a   Lu, Chien Hung ^a   Lee, Wei Ying ^a   Hsu, Chien Chi ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Acceptability; agomelatine; efficacy; major depressive disorder; meta analysis; safety

Indexed keywords

AGOMELATINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT;

ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV; FOLLOW UP; HUMAN; LEEDS SLEEP EVALUATION QUESTIONNAIRE; MAJOR DEPRESSION; META ANALYSIS; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT RESPONSE; ADULT; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ACETAMIDES; ADULT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN AND NORADRENALINE REUPTAKE INHIBITORS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84903538198     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1177/0004867414525837     Document Type: Article

References (47)

1. American Psychiatric Association. (2010) Practice guideline for the treatment of patients with major depressive disorder. Available at: http://psychiatryonline.org/data/Books/prac/PG-Depression3rdEd.pdf (accessed 15 February 2014).
2. Carney RM, Shelton RC. Agomelatine for the treatment of major depressive disorder. Expert Opinion on Pharmacotherapy. 2011 ; 12: 2411-2419
3. Corruble E, de Bodinat C, Belaidi C, et al. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: A 24-wk randomized, controlled, double-blind trial. International Journal of Neuropsychopharmacology. 2013 ; 16: 2219-2234
4. Demyttenaere K. Agomelatine: A narrative review. European Neuropsychopharmacology. 2011 ; 21: S703 - S709
5. Demyttenaere K, Corruble E, Hale A, et al. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. CNS Spectrums. 2013 ; 18: 163-170
6. Di Giannantonio M, Martinotti G. Anhedonia and major depression: the role of agomelatine. European Neuropsychopharmacology. 2012 ; 22: S505 - S510
7. Di Giannantonio M, Di Iorio G, Guglielmo R, et al. Major depressive disorder, anhedonia and agomelatine: An open-label study. Journal of Biological Regulators and Homeostatic Agents. 2011 ; 25: 109-114
8. European Medicines Agency (2001) ICH Topic E 10. Step 5. Note for guidance on choice of control group in clinical trials (CPMP/ICH/364/96). Available at: www.ema.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500002925.pdf (accessed on 15 February 2014).
9. European Medicines Agency (2008) CHMP assessment report for valdoxan. Available at: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/000915/WC500046226.pdf (accessed 14 February 2014)..
10. GartlehnerGHansenRAMorganLC. (2011) Second-generation antidepressants in the pharmacologic treatment of adult depression: An update of the 2007 Comparative Effectiveness Review. Available at: http://effectivehealthcare.ahrq. gov/ehc/products/210/862/CER46-Antidepressants-Update-execsumm.pdf (accessed 14 February 2014).
11. Goodwin GM, Emsley R, Rembry S, et al. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry. 2009 ; 70: 1128-1137
12. Gouin JP, Connors J, Kiecolt-Glaser JK, et al. Altered expression of circadian rhythm genes among individuals with a history of depression. Journal of Affective Disorders. 2010 ; 126: 161-166
13. Hale A, Corral RM, Mencacci C, et al. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, double-blind study. International Clinical Psychopharmacology. 2010 ; 25: 305-314
14. Hickie IB, Rogers NL. Novel melatonin-based therapies: Potential advances in the treatment of major depression. Lancet. 2011 ; 378: 621-631
15. Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Safety. 2011 ; 34: 709-731
16. Karaiskos D, Tzavellas E, Ilias I, et al. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. International Journal of Clinical Practice. 2013 ; 67: 257-260
17. Kasper S, Hamon M. Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action. World Journal of Biological Psychiatry. 2009 ; 10: 117-126
18. Kasper S, Corruble E, Hale A, et al. Antidepressant efficacy of agomelatine versus SSRI/SNRI: Results from a pooled analysis of head-to-head studies without a placebo control. International Clinical Psychopharmacology. 2013 ; 28: 12-19
19. Kasper S, Hajak G, Wulff K, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. Journal of Clinical Psychiatry. 2010 ; 71: 109-120
20. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. European Neuropsychopharmacology. 2006 ; 16: 93-100
21. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: Potential for clinical effectiveness. CNS Drugs. 2010 ; 24: 479-499
22. Kennedy SH, Rizvi S, Fulton K, et al. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology. 2008 ; 28: 329-333
23. Khan A, Detke M, Khan SR, et al. Placebo response and antidepressant clinical trial outcome. Journal of Nervous and Mental Disease. 2003 ; 191: 211-218
24. Koesters M, Guaiana G, Cipriani A, et al. Agomelatine efficacy and acceptability revisited: Systematic review and meta-analysis of published and unpublished randomised trials. British Journal of Psychiatry. 2013 ; 203: 179-187
25. Langan J, Shajahan P, Martin D, et al. Agomelatine in unipolar depression in clinical practice: a retrospective chart review. Therapeutic Advances in Psychopharmacology. 2011 ; 1: 175-180
26. Laux G. The antidepressant agomelatine in daily practice: Results of the non-interventional study VIVALDI. Pharmacopsychiatry. 2012 ; 45: 284-291
27. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry. 2007 ; 68: 1723-1732
28. Lôo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. International Clinical Psychopharmacology. 2002 ; 17: 239-247
29. McAllister-Williams RH, Baldwin DS, Haddad PM, et al. The use of antidepressants in clinical practice: Focus on agomelatine. Human Psychopharmacology. 2010 ; 25: 95-102
30. Martinotti G, Sepede G, Gambi F, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. Journal of Clinical Psychopharmacology. 2012 ; 32: 487-491
31. Mathers C, Fat DM, Boerma J The Global Burden of Disease: 2004 Update. Geneva: World Health Organization ; 2008 :
32. Montgomery SA, Kasper S. Severe depression and antidepressants: Focus on a pooled analysis of placebo-controlled studies on agomelatine. International Clinical Psychopharmacology. 2007 ; 22: 283-291
33. Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. International Clinical Psychopharmacology. 2009 ; 24: 111-118
34. Montgomery SA, Kennedy SH, Burrows GD, et al. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. International Clinical Psychopharmacology. 2004 ; 19: 271-280
35. Novartis (2009) Agomelatine. Study No: CAGO178A2303 (unpublished study). Available at: www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do? trialResult=2659 (accessed 15 February 2014).
36. Novartis (2010) Agomelatine. Study No: CAGO178A2304 (unpublished study). Norvatis. Available at: www.novctrd.com/ctrdWebApp/clinicaltrialrepository/ displayFile.do?trialResult=3420 (accessed 15 February 2014).
37. Nutt DJ, Davidson JR, Gelenberg AJ, et al. International consensus statement on major depressive disorder. Journal of Clinical Psychiatry. 2010 ; 71: e08
38. Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology. 2011 ; 26: 252-262
39. Quera Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: An open-label study. International Journal of Neuropsychopharmacology. 2007 ; 10: 691-696
40. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry. 2006 ; 163: 1905-1917
41. Rutherford BR, Sneed JR, Roose SP. Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychotherapy and Psychosomatics. 2009 ; 78: 172-181
42. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: Meta-analysis and appraisal. International Journal of Neuropsychopharmacology. 2011 ; 15: 417-428
43. Sinyor M, Schaffer A, Smart KA, et al. Sponsorship, antidepressant dose, and outcome in major depressive disorder: Meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry. 2012 ; 73: e277 - e287
44. Stahl SM, Fava M, Trivedi MH, et al. Agomelatine in the treatment of major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. Journal of Clinical Psychiatry. 2010 ; 71: 616-626
45. Stein DJ, Picarel-Blanchot F, Kennedy SH. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Human Psychopharmacology. 2013 ; 28: 151-159
46. Waraich P, Goldner EM, Somers JM, et al. Prevalence and incidence studies of mood disorders: A systematic review of the literature. Canadian Journal of Psychiatry/Revue Canadienne de Psychiatrie. 2004 ; 49: 124-138
47. Zajecka J, Schatzberg A, Stahl S, et al. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology. 2010 ; 30: 135-144